Predictive value of PfEMP1 antibody profiles for the course of controlled human malaria infections
Antibody-mediated immunity directed against Plasmodium falciparum erythrocyte membrane protein 1 (PfEMP1) is an important immune mechanism for protection against clinical malaria and control of parasitemia. Current studies on PfEMP1-based immunity are constrained by the protein's high molecular weight, complex multidomain architecture, and extensive polymorphism. Controlled human malaria infection (CHMI) studies uniquely enable the assessment of strain-specific PfEMP1 immunity prior to exposure and its correlation with infection outcomes using the same parasite strain. In this study, different serological assays targeting both full-length native PfEMP1 and individual domains were applied to plasma samples obtained prior to challenge infection at study baseline from 25 individuals enrolled in a CHMI study of PfSPZ Challenge (NF54), that included malaria-naïve Europeans and lifelong malaria-exposed Africans with varying degrees of immunity. All assays showed strong predictive value of both PfEMP1 antibody levels and breadth at study baseline for CHMI outcome. A random forest machine learning analysis of antibody recognition profiles, measured by AlphaScreen nearly covering all extracellular PfEMP1 domains of the NF54-CHMI parasite strain, suggested that a broad antibody repertoire, including antibodies against the most diversified group B PfEMP1s, represents a discriminative feature distinguishing volunteers with high versus low susceptibility to CHMI. In parasites re-isolated from the volunteers, dominant var transcripts encoded PfEMP1 variants are not recognized by the individuals' pre-existing antibodies at study baseline. Given that the CHMI strain NF54 predominantly expresses B-type var genes at the onset of blood-stage infection, effective control of CHMI was associated with a broad antibody repertoire, particularly including antibodies targeting B-type PfEMP1. In line with the "hole-in-the-wall" theory, this likely reflects an antibody-mediated restriction of the parasite population emerging from the liver to parasites expressing PfEMP1 variants not previously encountered by the host immune system.
Authors
- Stephen L. Hoffman (ORCID: https://orcid.org/0000-0002-0700-9505)
- Eizo Takashima (ORCID: https://orcid.org/0000-0001-9070-8499)
- Meral Esen (ORCID: https://orcid.org/0000-0001-8638-4719)
- Iris Bruchhaus (ORCID: https://orcid.org/0000-0002-3363-7409)
- Tim‐Wolf Gilberger (ORCID: https://orcid.org/0000-0002-7965-8272)
- Takafumi Tsuboi (ORCID: https://orcid.org/0000-0002-7415-1325)
- Anna Bachmann (ORCID: https://orcid.org/0000-0001-8397-7308)
- Charlotte Wapler
- Jean Claude Dejon-Agobé
- Hannah Honner (ORCID: https://orcid.org/0009-0003-3169-8771)
- Benjamin Mordmüller
- B. Kim Lee Sim (ORCID: https://orcid.org/0000-0002-8598-8905)
- Ralf Krumkamp
- Thomas Lavstsen
- Hikaru Nagaoka
- Jana Held
- Peter G. Kremsner
- Jeannot Fréjus Zinsou
- Yabo J. Honkpehedji
- Louise Turner
- Bertrand Lell
- Yannick D. Höppner
- Heidrun von Thien
Institutions
- University of Copenhagen (DK)
- Radboud University Nijmegen (NL)
- Universität Hamburg (DE)
- Leiden University Medical Center (NL)
- Copenhagen University Hospital (DK)
- Radboud University Medical Center (NL)
- Sanaria (US)
- Centre de Recherche Médicales de Lambaréné (GA)
- Radboud Institute for Molecular Life Sciences (NL)
- German Center for Infection Research (DE)
- Centre for Structural Systems Biology (DE)
- Ehime University (JP)
- Medical University of Vienna (AT)
- University of Tübingen (DE)
- Bernhard Nocht Institute for Tropical Medicine (DE)
Publication Details
- Journal
- PLoS Pathogens
- Published
- 2026-06-24
- DOI
- https://doi.org/10.1371/journal.ppat.1014377
- Primary Topic
- Malaria Research and Control
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Deutsches Zentrum für Infektionsforschung
- Japan Agency for Medical Research and Development
- Deutsche Forschungsgemeinschaft
- Bundesministerium für Bildung und Forschung
- Novo Nordisk
- Danmarks Frie Forskningsfond
- Kirsten og Freddy Johansens Fond
- Novo Nordisk Fonden
- National Institutes of Health
- National Institute of Allergy and Infectious Diseases
- European and Developing Countries Clinical Trials Partnership